Quality by Design for Biologics and Biosimilars - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Quality by Design for Biologics and Biosimilars
The author provides an overview of QbD implmentation for biopharmaceuticals.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 64-68


The economics of developing and commercializing follow-on biologics, in particular in Asia, necessitate that manufacturers cannot merely replicate process and product development practices that have been established at US and European manufacturers. The raised expectations of the regulatory agencies, as represented by the PAT and ICH guidelines, will need to be met. For QbD implementation, the next decade is likely to witness an evolution into a more cost-efficient approach, driven by innovation in the areas mentioned herein and beyond.

Anurag S. Rathore is a faculty member in the Department of Chemical Engineering at the Indian Institute of Technology, Hauz Khas, New Delhi, 110016, India, +91 96 5077 0650,


1. FDA, Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (Rockville, MD, September, 2004.

2. ICH, Q8 Pharmaceutical Development (Geneva, November, 2007).

3. ICH, Q9 Quality Risk Management (Geneva, June 2006).

4. ICH, Q10 Pharmaceutical Quality Systems (Geneva, September, 2006).

5. A.S. Rathore, Pharm. Technol. Eur. 22 (2) 2010.

6. A.S. Rathore and H. Winkle, Nature Biotechnol. 27, 26-34 (2009).

7. S. Kozlowski and P. Swann, "Considerations for Biotechnology Product Quality by Design," in Quality by Design for Biopharmaceuticals: Perspectives and Case Studies, Eds. A.S. Rathore and R. Mhatre (Wiley Interscience 2009), pp. 9-30.

8. A.S. Rathore, Trends in Biotechnol. 27 (2009), 546–553.

9. G. Walsh, Nature Biotechnol. 28 (2010), 917–924.

10. A.S. Rathore, Trends in Biotechnol. 27 (2009), 698–705.

11. R. Bhambure, K. Kumar, and A. S. Rathore, Trends in Biotechnol. 27 (2010), doi:10.1016/j.tibtech.2010.12.001.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here